- Global Pharma News & Resources

Adjustment of conversion price of convertible bond 2020/2023 (ISIN DE000A3E46M4) to EUR 1.61 after implemented capital increase

DGAP-News: aap Implantate AG / Key word(s): Miscellaneous
25.11.2021 / 16:07
The issuer is solely responsible for the content of this announcement.

The convertible bond 2020/2023 of aap Implantate AG ("aap" or the "Company") is divided into partial bearer bonds ("bonds") with a nominal value of EUR 1.75 each, ranking pari passu among themselves. In accordance to the terms and conditions of the bonds, each bondholder is entitled to convert each bond initially at its nominal value into ordinary bearer shares (no-par value shares) in aap with a pro rata amount of the share capital of EUR 1.00.

On the basis of the capital increase against cash contributions with subscription and oversubscription rights of the Company's shareholders out of the authorized capital 2019/I resolved by the Management Board and Supervisory Board on 27 September 2021, aap published on 29 September 2021 a subscription offer for up to 1,500,000 new ordinary bearer shares (no-par value shares) in aap with a pro rata amount of the share capital of EUR 1.00 per share. Shareholders were granted the statutory subscription right. 1,500,000 new shares were issued at a subscription price of EUR 3.30.

Section 11 of the terms and conditions of the bonds provides for this case that the creditors of the bonds are protected against dilution. In addition to the granting of a subscription right or the payment of a subscription right compensation amount, the adjustment of the conversion price is also possible. aap hereby announces that the conversion price of the bonds has been reduced by EUR 0.14 to EUR 1.61 per share in accordance with the terms and conditions of the bonds.


Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For queries, please contact:
aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; Email:

25.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
ISIN: DE000A3H2101
WKN: A3H210
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1252044

End of News DGAP News Service

Editor Details

Last Updated: 25-Nov-2021